Related Experiment Video
Updated: Jul 17, 2026
06:52
Discovery of Driver Genes in Colorectal HT29-derived Cancer Stem-Like Tumorspheres
Published on: July 22, 2020
Tumour budding in colorectal carcinoma
1Institute of Pathology, University of Rostock, Rostock, Germany. friedrich.prall@med.uni-rostock.de
Histopathology
|January 6, 2007
Summary
Tumour budding, where cancer cells detach at the invasion front of colorectal adenocarcinomas, is a significant adverse prognostic factor. This review explores its morphology and link to epithelial-mesenchymal transition for routine pathology.
Area of Science:
- Oncology
- Pathology
- Cancer Biology
Background:
- Tumour budding involves detached tumor cells at the invasion front of colorectal adenocarcinomas.
- This morphological feature is recognized as a strong adverse prognostic indicator.
- It is biologically linked to the epithelial-mesenchymal transition (EMT).
Purpose of the Study:
- To review the morphological features of tumour budding in colorectal carcinoma resection specimens.
- To contextualize these features within current knowledge of EMT and colorectal cancer molecular pathology.
- To analyze published clinicopathological studies on tumour budding as a prognostic factor.
Main Methods:
- Morphological analysis of tumour budding by surgical pathologists.
- Review of literature on epithelial-mesenchymal transition.
- Systematic analysis of clinicopathological studies.
Main Results:
- Tumour budding presents as single cells or small aggregates detached from neoplastic glands.
- The process is closely associated with EMT, a key mechanism in cancer progression.
- Published studies indicate tumour budding's potential as a prognostic marker.
Conclusions:
- Tumour budding is a critical morphological feature in colorectal adenocarcinomas.
- Understanding its link to EMT enhances prognostic accuracy.
- Tumour budding shows promise as a routine prognostic factor in surgical pathology for colorectal cancer.
More Related Videos
Related Concept Videos
02:07Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
02:07Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
02:30Metastasis
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
02:40Cancer Stem Cells and Tumor Maintenance
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
02:40Cancer Stem Cells and Tumor Maintenance
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
02:21Cancers Originate from Somatic Mutations in a Single Cell
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...